Thomas D Brothers1, John Fraser2, Duncan Webster2. 1. Division of General Internal Medicine and Clinician Investigator Program (Brothers), and Division of Infectious Diseases (Webster), Department of Medicine, Dalhousie University; Mobile Outreach Street Health (Fraser), North End Community Health Centre, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), Institute of Epidemiology & Health Care, University College London, London, UK; Division of Infectious Diseases (Webster), Saint John Regional Hospital, Saint John, NB thomas.brothers@dal.ca. 2. Division of General Internal Medicine and Clinician Investigator Program (Brothers), and Division of Infectious Diseases (Webster), Department of Medicine, Dalhousie University; Mobile Outreach Street Health (Fraser), North End Community Health Centre, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), Institute of Epidemiology & Health Care, University College London, London, UK; Division of Infectious Diseases (Webster), Saint John Regional Hospital, Saint John, NB.
Injection drug use and associated hospital admissions are increasingly common in Canada
The number of people who inject drugs in Canada increased from 130 000 in 2011 to 171 900 in 2016.1 Reported hospital admissions for patients with injection-associated infective endocarditis in Ontario increased 5-fold from 34 in 1997 to 176 in 2014.2
People who inject drugs may not be comfortable disclosing substance use
Clinicians should use a nonjudgmental approach to ask their patients about type, quantity and frequency of substance use. Illicit substance use is stigmatized and criminalized, which affects hospital care.3,4 People who inject drugs ask for care that prioritizes trust and relationships, recognizes power imbalances and gives patients space.3
Starting treatment for substance use disorders in hospital improves outcomes
A randomized controlled trial5 and several cohort studies4,6 found inhospital initiation of opioid agonist treatment (e.g., buprenorphine or methadone) for opioid use disorder was associated with increased engagement with treatment and decreased readmissions or death, compared with outpatient referrals. All physicians can prescribe buprenorphine or methadone in hospital, although some provincial medical regulators require certification to initiate opioid agonist treatment. Addiction medicine consultation services can assist with complex diagnosis and management issues, including stimulant and polysubstance use disorders.4
Effectively treating opioid withdrawal reduces premature patient-initiated discharges against medical advice
People who inject drugs describe leaving hospital prematurely because of undertreated withdrawal and pain.3 Most people who inject drugs use opioids,1 and opioid medications are far more effective than nonopioids (e.g., clonidine) at relieving opioid withdrawal symptoms and facilitating hospital care.3,4 If patients decline opioid agonist treatment, physicians should consider frequent dosing of short-acting opioids (e.g., hydromorphone every 3 h), titrated to symptom relief.4 Treating withdrawal or pain with opioids does not “worsen” addiction. Shared decision-making is essential.4
Hospitals should offer harm reduction services
Hospitals need to change traditional abstinence-only policies.4 Harm reduction services, such as peer support, sterile injection equipment and disposal containers, take-home naloxone kits and supervised consumption facilities, should be offered by hospitals. When provided, these evidence-based services help reduce risks of infection and overdose among inpatients.4
Authors: Laura R Marks; Satish Munigala; David K Warren; Stephen Y Liang; Evan S Schwarz; Michael J Durkin Journal: Clin Infect Dis Date: 2019-05-17 Impact factor: 9.079
Authors: Thomas D Brothers; Dan Lewer; Nicola Jones; Samantha Colledge-Frisby; Michael Farrell; Matthew Hickman; Duncan Webster; Andrew Hayward; Louisa Degenhardt Journal: PLoS Med Date: 2022-07-19 Impact factor: 11.613
Authors: Thomas D Brothers; Kimiko Mosseler; Susan Kirkland; Patti Melanson; Lisa Barrett; Duncan Webster Journal: PLoS One Date: 2022-01-26 Impact factor: 3.240
Authors: Dan Lewer; Brian Eastwood; Martin White; Thomas D Brothers; Martin McCusker; Caroline Copeland; Michael Farrell; Irene Petersen Journal: PLoS Med Date: 2021-10-05 Impact factor: 11.069
Authors: Thomas D Brothers; Malcolm Leaman; Matthew Bonn; Dan Lewer; Jacqueline Atkinson; John Fraser; Amy Gillis; Michael Gniewek; Leisha Hawker; Heather Hayman; Peter Jorna; David Martell; Tiffany O'Donnell; Helen Rivers-Bowerman; Leah Genge Journal: Drug Alcohol Depend Date: 2022-04-07 Impact factor: 4.852